Watch PTPI. Know when insiders buy.
One email the day a filing lands. Free.
PTPI
Petros Pharmaceuticals, Inc.
0.00
−0.00 −20.00%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $169KP/E 0.1DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$3.2MNET CASH $1.7M52W 0.00 – 0.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$989K | −$956K | −117.6% | -0.30 | −$864K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$1M | −$987K | — | -0.03 | −$784K | — | — | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$391K | −$337K | — | 0.39 | −$934K | — | — | Apr 15 |
| Q3 2025 · Sep 30 | — | — | — | −$991K | −$923K | — | -0.03 | −$1.1M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$1.8M | $5.4M | — | -1.20 | −$3M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$1.5M | −$2.3M | — | -9.37 | −$1.7M | — | — | May 13 |
| Q4 2024 · Dec 31derived | $725K | — | 63.5% | −$578K | −$9.3M | −3014.8% | -12.20 | $965K | $5K | $960K | Apr 15 |
| Q3 2024 · Sep 30 | $1.6M | −5.9% | 81.8% | −$1.2M | −$2.2M | — | -16.65 | −$771K | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $1.4M | — | 76.8% | −$1.3M | −$662K | — | -9.25 | −$1.7M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $1.4M | — | 76.1% | −$1.5M | −$2.2M | — | -42.19 | −$1.1M | — | — | May 15 |
| Q4 2023 · Dec 31derived | −$364K | — | 143.4% | −$5M | $318K | — | -1.62 | −$2.3M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | $1.7M | — | 75.6% | −$4.8M | −$4.5M | — | -2.85 | −$4M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$4.6M | $1.9M | — | -1.56 | −$6.7M | — | — | — | — |
| FY2024 · to Dec 31 | $5.1M | 76.3% | −$4.6M | −$14.3M | -280.1% | -83.47 | −$2.6M | $25K | −$2.6M | — | — |
| FY2023 · to Dec 31 | $5.8M | 72.0% | −$13.6M | −$8.2M | -140.2% | -6.35 | −$7.6M | — | — | — | — |
| FY2022 · to Dec 31 | $6M | 61.8% | −$19.9M | −$20M | -334.4% | -9.68 | −$12.8M | — | — | — | — |
| FY2021 · to Dec 31 | $7.8M | 79.5% | −$18M | −$9M | -115.0% | -8.25 | −$11.9M | — | — | — | — |
| FY2020 · to Dec 31 | $9.6M | 57.7% | −$17.3M | −$20.6M | -215.3% | -3.85 | −$15.3M | $5K | −$15.3M | — | — |
Every number comes from Petros Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.